Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
McKinsey
Baxter
Medtronic
Mallinckrodt

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Tremelimumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Tremelimumab: Sponsors, patents, clinical trial progress

Tremelimumab is an investigational drug.

There have been 136 clinical trials for Tremelimumab. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2015.

The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and M.D. Anderson Cancer Center.

There are fifty-two US patents protecting this investigational drug and nine hundred and ninety-four international patents.

Recent Clinical Trials for Tremelimumab
TitleSponsorPhase
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal CancerNational Cancer Institute (NCI)Phase 2
TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder CancerAstraZenecaPhase 1
TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder CancerDaniel George, MDPhase 1

See all Tremelimumab clinical trials

Clinical Trial Summary for Tremelimumab

Top disease conditions for Tremelimumab
Top clinical trial sponsors for Tremelimumab

See all Tremelimumab clinical trials

US Patents for Tremelimumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tremelimumab   Start Trial Immunoregulatory agents Flexus Biosciences, Inc. (Princeton, NJ)   Start Trial
Tremelimumab   Start Trial .beta.-glucan methods and compositions that affect the tumor microenvironment BIOTHERA, INC. (Eagan, MN)   Start Trial
Tremelimumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Tremelimumab   Start Trial Methods of using OX40 ligand encoding polynucleotides ModernaTX, Inc. (Cambridge, MA)   Start Trial
Tremelimumab   Start Trial Intralesional (Intratumoral) dinitrochlorobenzene and associated compounds coadministered with checkpoint inhibitors for cancer treatment including treatment of metastatic cutaneous cancers   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tremelimumab

Drugname Country Document Number Estimated Expiration Related US Patent
Tremelimumab Argentina 102536 2034-11-05   Start Trial
Tremelimumab Australia 2015342940 2034-11-05   Start Trial
Tremelimumab Brazil 112017008568 2034-11-05   Start Trial
Tremelimumab Canada 2964290 2034-11-05   Start Trial
Tremelimumab Chile 2017001124 2034-11-05   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Moodys
Express Scripts
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.